What is HUTCHMED (China) Limited's earnings per share (EPS)?

HUTCHMED (China) Limited (HMDCF) reported diluted earnings per share of $0.52 for fiscal year 2025. This represents a 1200.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

HUTCHMED (China) Limited (HMDCF) Financials

HMDCF

FY2025 annual

Revenue $548.5M -13.0% YoY

Net Income $456.9M +1111.0% YoY

EPS (Diluted) $0.52 +1200.0% YoY

Free Cash Flow -$78.8M -352.0% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Mar 5, 2026 Currency USD FYE December

Newest figures come from the 10-K for FY2025, filed Mar 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HMDCF SEC filings page.

HUTCHMED (China) Limited (HMDCF) reported $548.5M in revenue for fiscal year 2025, down 13.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HMDCF FY2025 2026-08-30

HUTCHMED’s reported 2025 profit diverges sharply from operations, leaving a cash-consuming business despite a strengthened balance sheet.

FY2025 net income reached $457M while operating cash flow was -$65M, showing reported profit was not produced by operating cash generation. Since FY2023, gross margin fell from 54.1% to 38.7% as free cash flow shifted from positive to negative, linking the earnings gap to weaker cash economics.

R&D spending declined from $302M in FY2023 to $148M in FY2025, but the cost reduction did not restore operating profitability. Operating income remained negative at -$39M, indicating the smaller research bill did not offset the lower revenue base or other operating costs.

Total assets rose to $1.75B while total liabilities were $502M in FY2025, so the balance sheet is financed more by equity than debt. A 5.0x current ratio alongside 0.1x debt-to-equity points to short-term coverage without relying heavily on borrowing.

Financial Health Signals

Financial health score not available

HUTCHMED (China) Limited does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

3.04

HUTCHMED (China) Limited scores 3.04, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.9B) relative to total liabilities ($501.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

HUTCHMED (China) Limited passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

$0.14used

For every $1 of reported earnings, HUTCHMED (China) Limited used $0.14 of operating cash (-$64.7M OCF vs $456.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage At Risk

N/A

HUTCHMED (China) Limited reported an operating loss of $39.2M against $2.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

None of these metrics is reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$71.3M

YoY-53.7%

QoQ-35.6%

5Y CAGR-3.5%

HUTCHMED (China) Limited held $71.3M in cash against $68.2M in long-term debt as of Q4 2025.

Shares Outstanding

872M

YoY+0.1%

HUTCHMED (China) Limited had 872M shares outstanding in Q4 2025. This represents an increase of 0.1% from the same quarter a year earlier.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

HMDCF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HMDCF quarterly income statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	$548.5M-13.0%	$630.2M-24.8%	$838.0M+96.5%	$426.4M+19.7%	$356.1M+56.2%	$228.0M+11.3%	$204.9M-4.3%	$214.1M-11.2%	$241.2M+11.6%	$216.1M+21.3%	$178.2M+104.1%	$87.3M
Cost of Revenue	$336.3M-3.6%	$348.9M-9.3%	$384.4M+23.6%	$311.1M	N/A	N/A	N/A	N/A	$169.8M+13.8%	$149.1M+42.2%	$104.9M+96.1%	$53.5M
Gross Profit	$212.2M-24.6%	$281.3M-38.0%	$453.6M+293.3%	$115.3M	N/A	N/A	N/A	N/A	$71.4M+6.7%	$66.9M-8.7%	$73.3M+116.7%	$33.9M
R&D Expenses	$148.3M-30.1%	$212.1M-29.8%	$302.0M-21.9%	$386.9M+29.4%	$299.1M+71.1%	$174.8M+26.5%	$138.2M+21.0%	$114.2M+51.2%	$75.5M+12.9%	$66.9M+41.2%	$47.4M+58.3%	$29.9M
SG&A Expenses	$66.7M+3.8%	$64.3M-19.4%	$79.8M-13.4%	$92.2M+3.2%	$89.3M+78.5%	$50.0M+27.6%	$39.2M+26.9%	$30.9M+29.0%	$24.0M+11.0%	$21.6M+10.0%	$19.6M+54.3%	$12.7M
Operating Income	-$39.2M+10.4%	-$43.7M-337.9%	$18.4M+104.5%	-$407.7M-24.2%	-$328.3M-66.9%	-$196.7M-34.3%	-$146.4M-58.0%	-$92.6M-73.4%	-$53.4M-14.4%	-$46.7M-377.9%	-$9.8M+46.5%	-$18.3M
EBITDA	-$25.9M+17.6%	-$31.4M-218.0%	$26.6M+106.7%	-$399.0M-24.3%	-$321.1M-68.5%	-$190.6M-34.8%	-$141.4M-58.8%	-$89.1M-75.2%	-$50.8M-14.6%	-$44.4M-471.9%	-$7.8M+54.4%	-$17.0M
Interest Expense	$2.9M-0.2%	$2.9M+278.4%	$759K+16.4%	$652K+10.1%	$592K-24.8%	$787K-23.6%	$1.0M+2.1%	$1.0M-30.7%	$1.5M-10.8%	$1.6M+16.2%	$1.4M-7.4%	$1.5M
Income Tax	$63.6M+784.5%	$7.2M+59.5%	$4.5M+1693.3%	-$283K-102.4%	$11.9M+146.8%	$4.8M+47.5%	$3.3M-17.4%	$4.0M+28.7%	$3.1M-28.9%	$4.3M+169.8%	$1.6M+19.5%	$1.3M
Net Income	$456.9M+1111.0%	$37.7M-62.6%	$100.8M+127.9%	-$360.8M-85.4%	-$194.6M-54.8%	-$125.7M-18.6%	-$106.0M-41.7%	-$74.8M-179.8%	-$26.7M-328.6%	$11.7M+46.4%	$8.0M+209.4%	-$7.3M
EPS (Basic)	$0.53+1225.0%	$0.04-66.7%	$0.12+127.9%	-$0.43-72.0%	-$0.25-38.9%	-$0.18-12.5%	-$0.16-45.5%	-$0.11-175.0%	-$0.04-120.0%	$0.20+131.3%	-$0.64-3.2%	-$0.62
EPS (Diluted)	$0.52+1200.0%	$0.04-66.7%	$0.12+127.9%	-$0.43-72.0%	-$0.25-38.9%	-$0.18-12.5%	-$0.16	-$1.13-162.8%	-$0.43-315.0%	$0.20+131.3%	-$0.64-3.2%	-$0.62
Diluted Shares (Avg)	873M0.0%	873M+0.4%	869M+2.6%	847M+6.9%	793M+13.6%	698M+4.8%	666M	66M+7.6%	62M+2.9%	60M+9.7%	55M+4.0%	53M

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

HMDCF Balance Sheet

HMDCF quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$1.8B+37.6%	$1.3B-0.4%	$1.3B+24.3%	$1.0B-25.0%	$1.4B+89.6%	$724.1M+55.7%	$465.1M-12.6%	$532.1M-11.0%	$597.9M+74.6%	$342.4M+49.1%	$229.6M	N/A
Current Assets	$1.6B+47.0%	$1.1B-2.8%	$1.1B+30.6%	$839.9M-30.7%	$1.2B+128.4%	$530.7M+67.4%	$317.0M-14.4%	$370.5M-14.3%	$432.2M+158.2%	$167.4M+87.0%	$89.5M	N/A
Cash & Equivalents	$71.3M-53.7%	$154.0M-45.7%	$283.6M-9.5%	$313.3M-17.0%	$377.5M+60.2%	$235.6M+94.5%	$121.2M+40.8%	$86.0M+0.9%	$85.3M+7.3%	$79.4M+148.7%	$31.9M-18.0%	$38.9M
Short-Term Investments	$1.3B+90.0%	$682.2M+13.2%	$602.7M+89.7%	$317.7M-49.9%	$634.2M+217.8%	$199.5M+107.8%	$96.0M-55.3%	$214.9M-21.3%	$273.0M+1025.0%	$24.3M	$0	$0
Inventory	$41.1M-18.4%	$50.4M+0.3%	$50.3M-11.3%	$56.7M+58.6%	$35.8M+80.9%	$19.8M+22.0%	$16.2M+31.7%	$12.3M+4.4%	$11.8M-8.1%	$12.8M+34.2%	$9.6M	N/A
Accounts Receivable	$126.8M-18.5%	$155.5M+33.1%	$116.9M+19.3%	$98.0M+17.2%	$83.6M+74.6%	$47.9M+15.6%	$41.4M+3.1%	$40.2M+4.6%	$38.4M-5.9%	$40.8M+22.4%	$33.3M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$3.1M+4.1%	$3.0M-2.4%	$3.1M-2.3%	$3.1M-7.2%	$3.4M+2.2%	$3.3M+6.3%	$3.1M-2.3%	$3.2M-3.7%	$3.3M+5.5%	$3.1M-5.9%	$3.3M-2.9%	$3.4M
Total Liabilities	$501.8M-0.1%	$502.3M-6.3%	$536.4M+36.6%	$392.6M+17.8%	$333.1M+62.4%	$205.2M+34.8%	$152.2M+27.0%	$119.9M+6.1%	$113.0M-18.4%	$138.4M+8.7%	$127.3M	N/A
Current Liabilities	$315.8M-16.1%	$376.6M-6.6%	$403.0M+13.9%	$353.9M+13.6%	$311.7M+96.8%	$158.4M+40.0%	$113.1M+32.3%	$85.5M-18.3%	$104.6M+10.0%	$95.1M+17.3%	$81.1M	N/A
Non-Current Liabilities	$186.1M+47.9%	$125.8M-5.7%	$133.4M+244.8%	$38.7M+80.0%	$21.5M-54.1%	$46.8M+19.6%	$39.1M+13.8%	$34.4M+311.0%	$8.4M-80.7%	$43.3M-6.5%	$46.3M	N/A
Long-Term Debt	$68.2M+14.7%	$59.4M+23.3%	$48.2M+166.2%	$18.1M-32.7%	$26.9M+0.2%	$26.9M+0.2%	$26.8M+0.3%	$26.7M-10.8%	$30.0M+11.8%	$26.8M+0.2%	$26.8M	N/A
Total Equity	$1.2B+62.9%	$759.9M+4.0%	$730.5M+19.7%	$610.4M-38.2%	$986.9M+103.9%	$484.1M+68.1%	$288.0M-26.0%	$389.0M-15.8%	$461.7M+150.6%	$184.3M+121.1%	$83.4M+46.5%	$56.9M
Retained Earnings	-$378.6M+54.6%	-$833.2M+4.3%	-$870.9M+10.4%	-$971.5M-59.2%	-$610.3M-46.9%	-$415.6M-43.4%	-$289.7M-58.3%	-$183.0M-70.9%	-$107.1M-33.3%	-$80.4M+12.7%	-$92.0M	N/A

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Total Assets	$1.8B+37.6%	$1.8B+40.9%	$1.3B-0.4%	$1.3B-2.8%	$1.3B+24.3%	$1.3B+8.6%	$1.0B-25.0%	$1.2B-6.2%
Current Assets	$1.6B+47.0%	$1.6B+51.9%	$1.1B-2.8%	$1.0B-3.9%	$1.1B+30.6%	$1.1B+6.7%	$839.9M-30.7%	$1.0B-6.3%
Cash & Equivalents	$71.3M-53.7%	$110.7M-45.7%	$154.0M-45.7%	$204.0M-8.5%	$283.6M-9.5%	$223.0M-52.3%	$313.3M-17.0%	$467.5M-20.4%
Short-Term Investments	$1.3B+90.0%	$1.3B+109.5%	$682.2M+13.2%	$598.5M-5.5%	$602.7M+89.7%	$633.2M+76.5%	$317.7M-49.9%	$358.7M-1.2%
Inventory	$41.1M-18.4%	$48.5M+4.3%	$50.4M+0.3%	$46.4M-13.8%	$50.3M-11.3%	$53.9M+17.3%	$56.7M+58.6%	$45.9M+80.1%
Accounts Receivable	$126.8M-18.5%	$147.0M-6.3%	$155.5M+33.1%	$156.9M+21.4%	$116.9M+19.3%	$129.2M+67.6%	$98.0M+17.2%	$77.1M+33.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$3.1M+4.1%	$3.1M+1.6%	$3.0M-2.4%	$3.0M-1.6%	$3.1M-2.3%	$3.1M-6.0%	$3.1M-7.2%	$3.3M-2.2%
Total Liabilities	$501.8M-0.1%	$534.0M+4.9%	$502.3M-6.3%	$508.9M+2.3%	$536.4M+36.6%	$497.5M+45.3%	$392.6M+17.8%	$342.5M+32.1%
Current Liabilities	$315.8M-16.1%	$342.3M-8.3%	$376.6M-6.6%	$373.3M+9.5%	$403.0M+13.9%	$340.9M+5.9%	$353.9M+13.6%	$321.9M+29.9%
Non-Current Liabilities	$186.1M+47.9%	$191.7M+41.4%	$125.8M-5.7%	$135.6M-13.4%	$133.4M+244.8%	$156.6M+659.2%	$38.7M+80.0%	$20.6M+79.7%
Long-Term Debt	$68.2M+14.7%	$67.8M+21.9%	$59.4M+23.3%	$55.6M+38.6%	$48.2M+166.2%	$40.1M+9504.5%	$18.1M-32.7%	$418K-98.4%
Total Equity	$1.2B+62.9%	$1.2B+66.1%	$759.9M+4.0%	$740.1M-5.4%	$730.5M+19.7%	$782.0M-2.2%	$610.4M-38.2%	$799.7M-18.8%
Retained Earnings	-$378.6M+54.6%	-$380.3M+55.0%	-$833.2M+4.3%	-$845.1M-5.2%	-$870.9M+10.4%	-$803.1M-3.9%	-$971.5M-59.2%	-$773.2M-49.3%

HMDCF Cash Flow Statement

HMDCF quarterly cash flow statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$64.7M-13109.5%	$497K-99.8%	$219.3M+181.6%	-$268.6M-31.5%	-$204.2M-229.0%	-$62.1M+23.3%	-$80.9M-146.3%	-$32.8M-267.3%	-$8.9M+6.5%	-$9.6M-2.0%	-$9.4M-212.3%	$8.4M
Depreciation & Amortization	$13.3M+7.8%	$12.3M+50.4%	$8.2M-5.3%	$8.7M+20.5%	$7.2M+18.6%	$6.1M+22.6%	$4.9M+37.7%	$3.6M+39.3%	$2.6M+10.1%	$2.3M+16.2%	$2.0M+59.3%	$1.3M
Capital Expenditures	$14.1M-21.1%	$17.9M-45.0%	$32.6M-11.1%	$36.7M+123.5%	$16.4M+106.3%	$7.9M-7.2%	$8.6M+34.6%	$6.4M+26.8%	$5.0M+16.0%	$4.3M+30.2%	$3.3M-10.9%	$3.7M
Free Cash Flow	-$78.8M-352.0%	-$17.4M-109.3%	$186.6M+161.1%	-$305.3M-38.4%	-$220.6M-215.1%	-$70.0M+21.8%	-$89.5M-128.2%	-$39.2M-180.8%	-$14.0M-0.5%	-$13.9M-9.3%	-$12.7M-374.5%	$4.6M
Investing Cash Flow	-$29.4M+69.4%	-$96.1M+67.0%	-$291.1M-198.2%	$296.6M+196.8%	-$306.3M-144.2%	-$125.4M-205.4%	$119.0M+172.1%	$43.8M+116.8%	-$260.8M-676.2%	-$33.6M-479.4%	$8.9M+158.2%	-$15.2M
Financing Cash Flow	$7.8M+125.6%	-$30.7M-163.0%	$48.7M+158.8%	-$82.8M-112.7%	$650.0M+119.3%	$296.4M+19954.9%	-$1.5M+81.9%	-$8.2M-103.0%	$273.2M+195.6%	$92.4M+1789.5%	-$5.5M-753.5%	-$641K
Share Buybacks	N/A	$36.1M+297.6%	$9.1M-81.1%	$48.1M+76.1%	$27.3M+111.6%	$12.9M+3629.5%	$346K-93.7%	$5.5M+298.8%	$1.4M+126.3%	$604K-66.2%	$1.8M	N/A

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q

Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

HMDCF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HMDCF quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Gross Margin	38.7%-6.0pp	44.6%-9.5pp	54.1%+27.1pp	27.0%	N/A	N/A	N/A	N/A	29.6%-1.4pp	31.0%-10.2pp	41.2%+2.4pp	38.8%
Operating Margin	-7.1%-0.2pp	-6.9%-9.1pp	2.2%+97.8pp	-95.6%-3.4pp	-92.2%-5.9pp	-86.3%-14.8pp	-71.5%-28.2pp	-43.3%-21.1pp	-22.1%-0.5pp	-21.6%-16.1pp	-5.5%+15.4pp	-20.9%
Net Margin	83.3%+77.3pp	6.0%-6.0pp	12.0%+96.6pp	-84.6%-30.0pp	-54.7%+0.5pp	-55.1%-3.4pp	-51.7%-16.8pp	-34.9%-23.9pp	-11.1%-16.5pp	5.4%+0.9pp	4.5%+12.9pp	-8.4%
Return on Equity	36.9%+31.9pp	5.0%-8.8pp	13.8%+72.9pp	-59.1%-39.4pp	-19.7%+6.3pp	-26.0%+10.8pp	-36.8%-17.6pp	-19.2%-13.4pp	-5.8%-12.1pp	6.3%-3.2pp	9.6%+22.4pp	-12.8%
Return on Assets	26.1%+23.1pp	3.0%-4.9pp	7.9%+42.9pp	-35.0%-20.9pp	-14.2%+3.2pp	-17.4%+5.4pp	-22.8%-8.7pp	-14.1%-9.6pp	-4.5%-7.9pp	3.4%-0.1pp	3.5%	N/A
Current Ratio	4.96+2.1x	2.83+0.1x	2.72+0.3x	2.37-1.5x	3.89+0.5x	3.35+0.5x	2.80-1.5x	4.33+0.2x	4.13+2.4x	1.76+0.7x	1.10	N/A
Debt-to-Equity	0.060.0x	0.080.0x	0.070.0x	0.030.0x	0.030.0x	0.060.0x	0.090.0x	0.070.0x	0.06-0.1x	0.15-0.2x	0.32	N/A
Asset Turnover	0.31-0.2x	0.49-0.2x	0.65+0.2x	0.41+0.2x	0.26-0.1x	0.31-0.1x	0.440.0x	0.400.0x	0.40-0.2x	0.63-0.1x	0.78	N/A
FCF Margin	-14.4%-11.6pp	-2.8%-25.0pp	22.3%+93.9pp	-71.6%-9.6pp	-62.0%-31.2pp	-30.7%+13.0pp	-43.7%-25.4pp	-18.3%-12.5pp	-5.8%+0.6pp	-6.4%+0.7pp	-7.1%-12.4pp	5.3%

Metric	Q4'2510-K	Q2'2510-Q	Q4'2410-K	Q2'2410-Q	Q4'2310-K	Q2'2310-Q	Q4'2210-K	Q2'2210-Q
Current Ratio	4.96+2.1x	4.65+1.8x	2.83+0.1x	2.81-0.4x	2.72+0.3x	3.200.0x	2.37-1.5x	3.18-1.2x
Debt-to-Equity	0.060.0x	0.060.0x	0.080.0x	0.080.0x	0.070.0x	0.05+0.1x	0.030.0x	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.

Where HUTCHMED (China) Limited Ranks

Frequently Asked Questions

What is HUTCHMED (China) Limited's annual revenue?

HUTCHMED (China) Limited (HMDCF) reported $548.5M in total revenue for fiscal year 2025. This represents a -13.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is HUTCHMED (China) Limited's revenue growing?

HUTCHMED (China) Limited (HMDCF) revenue declined by 13.0% year-over-year, from $630.2M to $548.5M in fiscal year 2025.

Is HUTCHMED (China) Limited profitable?

Yes, HUTCHMED (China) Limited (HMDCF) reported a net income of $456.9M in fiscal year 2025, with a net profit margin of 83.3%.

What is HUTCHMED (China) Limited's EBITDA?

HUTCHMED (China) Limited (HMDCF) had EBITDA of -$25.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does HUTCHMED (China) Limited have?

As of fiscal year 2025, HUTCHMED (China) Limited (HMDCF) had $71.3M in cash and equivalents against $68.2M in long-term debt.

What is HUTCHMED (China) Limited's gross margin?

HUTCHMED (China) Limited (HMDCF) had a gross margin of 38.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is HUTCHMED (China) Limited's operating margin?

HUTCHMED (China) Limited (HMDCF) had an operating margin of -7.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is HUTCHMED (China) Limited's net profit margin?

HUTCHMED (China) Limited (HMDCF) had a net profit margin of 83.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is HUTCHMED (China) Limited's return on equity (ROE)?

HUTCHMED (China) Limited (HMDCF) has a return on equity of 36.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is HUTCHMED (China) Limited's free cash flow?

HUTCHMED (China) Limited (HMDCF) recorded an outflow of $78.8M in free cash flow during fiscal year 2025. This represents a -352.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is HUTCHMED (China) Limited's operating cash flow?

HUTCHMED (China) Limited (HMDCF) recorded an outflow of $64.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are HUTCHMED (China) Limited's total assets?

HUTCHMED (China) Limited (HMDCF) had $1.8B in total assets as of fiscal year 2025, including both current and long-term assets.

What are HUTCHMED (China) Limited's capital expenditures?

HUTCHMED (China) Limited (HMDCF) invested $14.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does HUTCHMED (China) Limited spend on research and development?

HUTCHMED (China) Limited (HMDCF) invested $148.3M in research and development during fiscal year 2025.

How many shares does HUTCHMED (China) Limited have outstanding?

HUTCHMED (China) Limited (HMDCF) had 872M shares outstanding as of fiscal year 2025.

What is HUTCHMED (China) Limited's current ratio?

HUTCHMED (China) Limited (HMDCF) had a current ratio of 4.96 as of fiscal year 2025, which is generally considered healthy.

What is HUTCHMED (China) Limited's debt-to-equity ratio?

HUTCHMED (China) Limited (HMDCF) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is HUTCHMED (China) Limited's return on assets (ROA)?

HUTCHMED (China) Limited (HMDCF) had a return on assets of 26.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is HUTCHMED (China) Limited's Altman Z-Score?

HUTCHMED (China) Limited (HMDCF) has an Altman Z-Score of 3.04, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is HUTCHMED (China) Limited's Piotroski F-Score?

HUTCHMED (China) Limited (HMDCF) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are HUTCHMED (China) Limited's earnings high quality?

For every $1 of reported earnings, HUTCHMED (China) Limited (HMDCF) used $0.14 of operating cash (-$64.7M OCF vs $456.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can HUTCHMED (China) Limited cover its interest payments?

HUTCHMED (China) Limited (HMDCF) reported an operating loss of $39.2M against $2.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.